221 related articles for article (PubMed ID: 21555375)
1. Characterization of bone metastases from rapid autopsies of prostate cancer patients.
Mehra R; Kumar-Sinha C; Shankar S; Lonigro RJ; Jing X; Philips NE; Siddiqui J; Han B; Cao X; Smith DC; Shah RB; Chinnaiyan AM; Pienta KJ
Clin Cancer Res; 2011 Jun; 17(12):3924-32. PubMed ID: 21555375
[TBL] [Abstract][Full Text] [Related]
2. Bone metastasis in prostate cancer: Recurring mitochondrial DNA mutation reveals selective pressure exerted by the bone microenvironment.
Arnold RS; Fedewa SA; Goodman M; Osunkoya AO; Kissick HT; Morrissey C; True LD; Petros JA
Bone; 2015 Sep; 78():81-6. PubMed ID: 25952970
[TBL] [Abstract][Full Text] [Related]
3. Bone Cell Activity in Clinical Prostate Cancer Bone Metastasis and Its Inverse Relation to Tumor Cell Androgen Receptor Activity.
Nordstrand A; Bovinder Ylitalo E; Thysell E; Jernberg E; Crnalic S; Widmark A; Bergh A; Lerner UH; Wikström P
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670000
[TBL] [Abstract][Full Text] [Related]
4. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival.
Hörnberg E; Ylitalo EB; Crnalic S; Antti H; Stattin P; Widmark A; Bergh A; Wikström P
PLoS One; 2011 Apr; 6(4):e19059. PubMed ID: 21552559
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone.
Roudier MP; True LD; Higano CS; Vesselle H; Ellis W; Lange P; Vessella RL
Hum Pathol; 2003 Jul; 34(7):646-53. PubMed ID: 12874759
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiles define molecular subtypes of prostate cancer bone metastases with different outcomes and morphology traceable back to the primary tumor.
Thysell E; Vidman L; Ylitalo EB; Jernberg E; Crnalic S; Iglesias-Gato D; Flores-Morales A; Stattin P; Egevad L; Widmark A; Rydén P; Bergh A; Wikström P
Mol Oncol; 2019 Aug; 13(8):1763-1777. PubMed ID: 31162796
[TBL] [Abstract][Full Text] [Related]
8. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping.
Cher ML; Bova GS; Moore DH; Small EJ; Carroll PR; Pin SS; Epstein JI; Isaacs WB; Jensen RH
Cancer Res; 1996 Jul; 56(13):3091-102. PubMed ID: 8674067
[TBL] [Abstract][Full Text] [Related]
9. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
Chung LW; Baseman A; Assikis V; Zhau HE
J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017
[TBL] [Abstract][Full Text] [Related]
10. Profiling of differential expression of messenger RNA in normal, benign, and metastatic prostate cell lines.
Chakrabarti R; Robles LD; Gibson J; Muroski M
Cancer Genet Cytogenet; 2002 Dec; 139(2):115-25. PubMed ID: 12550771
[TBL] [Abstract][Full Text] [Related]
11. LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis.
Thalmann GN; Sikes RA; Wu TT; Degeorges A; Chang SM; Ozen M; Pathak S; Chung LW
Prostate; 2000 Jul; 44(2):91-103 Jul 1;44(2). PubMed ID: 10881018
[TBL] [Abstract][Full Text] [Related]
12. Bone biopsy protocol for advanced prostate cancer in the era of precision medicine.
Sailer V; Schiffman MH; Kossai M; Cyrta J; Beg S; Sullivan B; Pua BB; Lee KS; Talenfeld AD; Nanus DM; Tagawa ST; Robinson BD; Rao RA; Pauli C; Bareja R; Beltran LS; Sigaras A; Eng KW; Elemento O; Sboner A; Rubin MA; Beltran H; Mosquera JM
Cancer; 2018 Mar; 124(5):1008-1015. PubMed ID: 29266381
[TBL] [Abstract][Full Text] [Related]
13. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study.
Heidenreich A; Pfister D; Porres D
J Urol; 2015 Mar; 193(3):832-8. PubMed ID: 25254935
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial DNA mutation stimulates prostate cancer growth in bone stromal environment.
Arnold RS; Sun CQ; Richards JC; Grigoriev G; Coleman IM; Nelson PS; Hsieh CL; Lee JK; Xu Z; Rogatko A; Osunkoya AO; Zayzafoon M; Chung L; Petros JA
Prostate; 2009 Jan; 69(1):1-11. PubMed ID: 18850577
[TBL] [Abstract][Full Text] [Related]
15. Identification of FBXL4 as a Metastasis Associated Gene in Prostate Cancer.
Stankiewicz E; Mao X; Mangham DC; Xu L; Yeste-Velasco M; Fisher G; North B; Chaplin T; Young B; Wang Y; Kaur Bansal J; Kudahetti S; Spencer L; Foster CS; Møller H; Scardino P; Oliver RT; Shamash J; Cuzick J; Cooper CS; Berney DM; Lu YJ
Sci Rep; 2017 Jul; 7(1):5124. PubMed ID: 28698647
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.
Armstrong AJ; Gupta S; Healy P; Kemeny G; Leith B; Zalutsky MR; Spritzer C; Davies C; Rothwell C; Ware K; Somarelli JA; Wood K; Ribar T; Giannakakou P; Zhang J; Gerber D; Anand M; Foo WC; Halabi S; Gregory SG; George DJ
PLoS One; 2019; 14(5):e0216934. PubMed ID: 31136607
[TBL] [Abstract][Full Text] [Related]
17. Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment.
Kfoury Y; Baryawno N; Severe N; Mei S; Gustafsson K; Hirz T; Brouse T; Scadden EW; Igolkina AA; Kokkaliaris K; Choi BD; Barkas N; Randolph MA; Shin JH; Saylor PJ; Scadden DT; Sykes DB; Kharchenko PV;
Cancer Cell; 2021 Nov; 39(11):1464-1478.e8. PubMed ID: 34719426
[TBL] [Abstract][Full Text] [Related]
18. Interphase cytogenetics of prostatic tumor progression: specific chromosomal abnormalities are involved in metastasis to the bone.
Alers JC; Krijtenburg PJ; Rosenberg C; Hop WC; Verkerk AM; Schröder FH; van der Kwast TH; Bosman FT; van Dekken H
Lab Invest; 1997 Nov; 77(5):437-48. PubMed ID: 9389787
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer.
Masuda H; Fukabori Y; Nakano K; Takezawa Y; CSuzuki T; Yamanaka H
Prostate; 2003 Mar; 54(4):268-74. PubMed ID: 12539225
[TBL] [Abstract][Full Text] [Related]
20. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program.
Shah RB; Mehra R; Chinnaiyan AM; Shen R; Ghosh D; Zhou M; Macvicar GR; Varambally S; Harwood J; Bismar TA; Kim R; Rubin MA; Pienta KJ
Cancer Res; 2004 Dec; 64(24):9209-16. PubMed ID: 15604294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
